Skip to main content
GutCited

Galactooligosaccharides (GOS) 관련 Irritable Bowel Syndrome (IBS)

B

Reduces IBS symptoms (pain, bloating, flatulence) in dose-dependent manner. 3.5 g/day showed better results than 7 g/day (excess fermentation at higher dose).

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dgalactooligosaccharides\u0026condition\u003Dibs'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

결론

Reduces IBS symptoms (pain, bloating, flatulence) in dose-dependent manner. 3.5 g/day showed better results than 7 g/day (excess fermentation at higher dose).

Key Study Findings

Review
Interplay of probiotics, prebiotics, synbiotics and postbiotics: a review of their therapeutic potential for gastrointestinal …
Dose: None vs: None Outcome: None 효과: None None

대상 집단: review of prebiotics, probiotics, synbiotics, postbiotics for gastrointestinal inflammation

Randomized Controlled Trial n=45 12 weeks Double-blind
All FODMAPs Aren't Created Equal: Results of a Randomized Reintroduction Trial in Patients With Irritable …
Dose: None vs: Sequential FODMAP subgroup reintroduction Outcome: Abdominal pain and bloating severity 효과: None p=0.007 fructans; p=0.04 GOS

대상 집단: IBS patients (Rome IV) who improved on FODMAP diet

Randomized Controlled Trial 4 weeks Double-blind
Is a Simplified, Less Restrictive Low FODMAP Diet Possible? Results From a Double-Blind, Pilot Randomized …
Dose: None vs: Traditional low FODMAP diet Outcome: IBS symptom response 효과: None None

대상 집단: IBS-D patients (Rome IV)

Systematic Review
Nutritional Interventions in Adult Patients With Irritable Bowel Syndrome: An Umbrella Review of Systematic Reviews …
Dose: None vs: Various Outcome: IBS symptom improvement 효과: Probiotics abdominal pain RR 4.04 (2.36-6.92) None

대상 집단: Adult IBS patients

Randomized Controlled Trial n=34 8 weeks Single-blind
A randomized trial of inulin for bowel symptoms, depression and quality of life in constipation …
Dose: 9.2 g/day total (4.6 g twice daily) vs: Maltodextrin 9.2 g/day placebo Outcome: IBS-SSS score and IBS-QoL score 효과: IBS-SSS: 267.3→195.8; IBS-QoL: 61.0→77.4 0.026 (IBS-SSS); 0.006 (QoL)

대상 집단: Adults with constipation-predominant IBS

Other
Biotechnological Tools for the Production of Low-FODMAP Wholegrain Wheat and Rye Cookies and Crackers.
Dose: None vs: Standard wholegrain flour products Outcome: FODMAP content reduction in cookies and crackers 효과: Up to 99.5% FODMAP reduction (wheat malt) None

대상 집단: Laboratory food science study (no human subjects)

Key Statistics

3

연구

400

참여자

Positive

B

등급

Referenced Papers

Foods (Basel, Switzerland) 2025 3 인용
Archivos argentinos de … 2024 3 인용
Frontline gastroenterology 2021 56 인용
Critical reviews in … 2019 35 인용
The American journal … 2019 15 인용
Journal of gastroenterology … 2017 181 인용
International journal of … 2017 146 인용
Journal of gastroenterology … 2017 32 인용
Current opinion in … 2017 24 인용
World journal of … 2016 238 인용
Scandinavian journal of … 2016 17 인용
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2016 2 인용
Journal of neurogastroenterology … 2015 60 인용
Menopause international 2009 29 인용
Alimentary pharmacology & … 2006 629 인용

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

일반적으로 사용되는 용량

general:
2.5-5 g/day
ibssupport:
3.5 g/day (optimal dose; higher doses may increase symptoms)
infantgutsupport:
0.24-0.48 g/100 mL formula (added to infant formula)

상한량: Well-tolerated up to 15 g/day; optimal dose appears to be 3.5-5 g/day

연구에서 사용된 용량

용량 기간 효과 N
None -- Positive --
None 12 weeks Negative 45
None 4 weeks Mixed --
None -- Positive --
9.2 g/day total (4.6 g twice daily) 8 weeks Positive 34
None -- Positive --
1e9 CFU/day + GOS 10 g/L -- Positive --
None -- Neutral --

권장 복용 시간: With meals; start with lower dose and increase gradually

Safety & Side Effects

보고된 부작용

  • Gas and bloating (especially above 5 g/day; dose-response is U-shaped)
  • Flatulence at higher doses
  • Abdominal cramping if dose increased too quickly
  • May worsen symptoms in FODMAP-sensitive individuals

알려진 상호작용

  • Other FODMAPs (cumulative fermentation in sensitive individuals)
  • Lactose-containing products (GOS is derived from lactose; generally safe for lactose-intolerant individuals as GOS itself is lactose-free)

일일 최대 섭취 허용량: Well-tolerated up to 15 g/day; optimal dose appears to be 3.5-5 g/day

건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.

Frequently Asked Questions

Does Galactooligosaccharides (GOS) help with Irritable Bowel Syndrome (IBS)?
Based on 3 studies with 400 participants, there is moderate evidence from clinical studies that Galactooligosaccharides (GOS) may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is B (Good Evidence).
How much Galactooligosaccharides (GOS) should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 2.5-5 g/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Galactooligosaccharides (GOS)?
Reported side effects may include Gas and bloating (especially above 5 g/day; dose-response is U-shaped), Flatulence at higher doses, Abdominal cramping if dose increased too quickly, May worsen symptoms in FODMAP-sensitive individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Galactooligosaccharides (GOS) and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 3 peer-reviewed studies with 400 total participants. The overall direction of effect is positive.

Related Evidence

FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.